RAPT Therapeutics Inc Total Assets
RAPT Therapeutics Inc total assets. Based on the latest financial reports, RAPT Therapeutics Inc (RAPT) holds total assets worth $165.74 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of RAPT Therapeutics Inc for the company's overall valuation and market capitalisation.
Total Assets of RAPT Therapeutics Inc (2017–2024)
Total assets of RAPT Therapeutics Inc from 2017 to 2024. This chart illustrates how RAPT Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See RAPT Therapeutics Inc stock quote for real-time trading data and today's change.
RAPT Therapeutics Inc - Asset Composition Analysis
RAPT Therapeutics Inc Total Assets Breakdown (December 2024)
RAPT Therapeutics Inc total assets breakdown as of December 2024. RAPT Therapeutics Inc's total assets of $165.74 Million consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how RAPT Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore RAPT Therapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RAPT Therapeutics Inc's current assets represent 97.9% of total assets in 2024, an increase from 95.7% in 2017.
- Cash Position: Cash and equivalents constituted 70.6% of total assets in 2024, down from 94.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
RAPT Therapeutics Inc Competitors by Total Assets
Key competitors of RAPT Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
RAPT Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.04 | 9.90 | 9.84 |
| Quick Ratio | 12.04 | 9.90 | 9.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $147.67 Million | $92.24 Million | $103.86 Million |
RAPT Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between RAPT Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.05 |
| Latest Market Cap to Assets Ratio | 6.99 |
| Asset Growth Rate (YoY) | 38.7% |
| Total Assets | $240.32 Million |
| Market Capitalization | $1.68 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values RAPT Therapeutics Inc's assets at a significant premium (6.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: RAPT Therapeutics Inc's assets grew by 38.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RAPT Therapeutics Inc (2017–2024)
The table below shows the annual total assets of RAPT Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $240.32 Million | +38.65% |
| 2023-12-31 | $173.33 Million | -34.89% |
| 2022-12-31 | $266.21 Million | +34.02% |
| 2021-12-31 | $198.64 Million | +66.96% |
| 2020-12-31 | $118.97 Million | +40.62% |
| 2019-12-31 | $84.60 Million | +21.54% |
| 2018-12-31 | $69.61 Million | +38.14% |
| 2017-12-31 | $50.39 Million | -- |
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) an… Read more